Compare and Contrast
Pair this feline OA mAB with Librela to cover both species in a multi-pet household
What is Solensia (Frunevetmab)
This type of monthly appointment creates a touchpoint for rechecks and client communication.
What are nurse/tech injection visits?
Librela is administered via this route.
What is subcutaneous?
By binding this neurotrophin, Librela prevents it from activating TrkA receptors to propagate pain signaling.
Compared with NSAIDs, Librela avoids these two common bloodwork concerns tied to hepatic and renal enzyme monitoring.
What are routine NSAID-related liver and kidney lab concerns (less emphasis on ALT/creatinine trends compared to NSAIDs; still monitor as clinically indicated)?
Name the Daily Oral therapy class Librela often replaces in dogs with GI sensitivity or poor compliance
For clients worried about cost, clinics can mention this owner-facing benefit program to help with affordability (if offered).
What is Petcare Rewards?
This is the per-visit dosing strategy: weight‑based fixed-dose syringe or mg/kg calculation?
What is weight‑band fixed dosing?
Because it’s a monoclonal antibody, Librela is primarily cleared by this metabolic pathway rather than hepatic cytochrome P450.
What is proteolytic catabolism (reticuloendothelial/protein degradation pathways)?
Clients should be told to contact the clinic if they observe these types of neurologic or hypersensitivity signs post-injection.
What are tremors, ataxia, seizures, facial swelling, hives, or collapse?
In multimodal OA care, this injectable anti-IL-31 therapy does not replace Librela because it treats a different condition.
What is Cytopoint (canine atopic dermatitis/itch)?
Stocking strategy tip: start with this number of weight bands most commonly seen in your patient base.
What is two to three bands aligned to practice demographics (e.g., 10–20 kg, 20–40 kg, 40–60 kg)?
True or False: Librela can be given with routine vaccines at the same visit.
What is True (per label guidance allowing co-administration with routine veterinary interventions; always follow label/local guidance)?
Compared to NSAIDs, mAbs like Librela typically have this type of gastrointestinal safety profile.
What is a favorable/low incidence of GI adverse effects?
For OA patients, name one nonpharmacologic modality you would combine with Librela for multimodal care.
What is weight management, physical rehab, omega-3s, acupuncture, or controlled exercise?
For perioperative pain, use labeled anesthetic/analgesic protocols instead; Librela is labeled for this indication only.
What is chronic osteoarthritis pain, not acute surgical pain?
When discussing expectations, staff should coach owners to look for improvements in these daily activities.
What are rising from rest, stairs, jumping, playing, or walk duration/pace?
When assessing efficacy, clinics often use this type of owner-reported questionnaire or scale.
What is a pain/mobility scale such as CBPI (Canine Brief Pain Inventory) or LOAD (Liverpool Osteoarthritis in Dogs)?
This is the typical onset expectation communicated to clients—some dogs show benefit after the first dose, but many need this number of doses to assess response.
What is two to three doses?
This is the typical approach if the dog shows partial response after one dose.
What is continue for two to three monthly doses while reassessing function and comfort?
When clients ask “Is it a steroid or NSAID?”, this is the best short answer.
What is “Neither — it’s a targeted monoclonal antibody against NGF”?
A common client objection to injectables is “I prefer pills.” Name one empathetic response highlighting Librela’s value
What is emphasizing once‑monthly convenience, consistent coverage, no daily pilling, and good GI tolerability?
Name one consideration before dosing in dogs with concurrent disease (e.g., severe uncontrolled disease).
What is clinician judgment/benefit-risk in dogs with significant comorbidities and monitoring?
Name one advantage of monthly injectable delivery relevant to caregiver burden or adherence.
What is improved compliance (no daily pills), predictable monthly visits, or reduced pilling stress?
Name one reason to file a pharmacovigilance report after treatment.
What is any suspected adverse event or lack of expected efficacy?